We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Fecal Immunochemical Test Assessed in Suspected Colorectal Cancer

By LabMedica International staff writers
Posted on 05 Nov 2020
Print article
Image: The HM-JACKarc analytical system is a compact bench top system that uses Integrated Sphere Latex Turbidimetry to measure fecal hemoglobin concentration using a highly sensitive latex reagent coated with polyclonal antibodies to human hemoglobin (Photo courtesy of Hitachi Chemical Diagnostics Systems).
Image: The HM-JACKarc analytical system is a compact bench top system that uses Integrated Sphere Latex Turbidimetry to measure fecal hemoglobin concentration using a highly sensitive latex reagent coated with polyclonal antibodies to human hemoglobin (Photo courtesy of Hitachi Chemical Diagnostics Systems).
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue.

The fecal immunochemical test (FIT) detects the globin component of hemoglobin (Hb) by immunoassay and can reliably measure the fecal Hb concentration (f-Hb) to the nearest microgram of Hb per gram of faces (µg/g). Since 2010, over 25 diagnostic accuracy studies have reported data on the use of FIT in symptomatic patients utilizing a range of cut-offs.

A team of medical scientists led by those at Croydon University Hospital (Croydon, UK) analyzed almost 10,000 patients referred to a specialist for suspected CRC symptoms that met criteria for urgent care. FIT sensitivity was maximized to 97.0% at the lowest fecal hemoglobin concentration cutoff of 2 µg/g. Between October 2017 and December 2019, 21,126 patients were sent recruitment packs, 13,219 (62.6%) returned FIT devices. Complete FIT and colonoscopy outcomes were available for 9,822 patients, who were included in the study results. Median age was 65 in the final cohort of kit-returning patients, 54% of whom were women.

FIT analysis was performed at one centralized laboratory where staff were blinded to patient clinical information. The HM-JACKarc analytical system (Hitachi Chemical Diagnostics Systems, Tokyo, Japan) was used to analyze all samples. The analytical working range is 7–400 µg/g. The limit of detection (LoD) of the assay is 2 µg/g and the limit of quantitation is 7 µg/g. The National Institute for Health and Care Excellence (NICE) recommended an f-Hb cut-off of 10 µg/g in the DG30 guidelines. Colonoscopy was chosen as the reference standard since it is acknowledged to be the gold-standard investigation for colorectal disease. Colonoscopists were blinded to the FIT results.

The team reported that incidence of CRC at colonoscopy was 3.3%. At fecal hemoglobin concentration cutoffs of 2, 10, and 150 µg/g, FIT positivity decreased from 37.2% to 19.0% and 7.6%, respectively. The positive predictive values of FIT for CRC was 8.7% at the 2 µg/g cutoff, 16.1% at the 10 µg/g cutoff, and 31.1% at the 150 µg/g cutoff. Respective negative predictive values were 99.8%, 99.6%, and 98.9%. In terms of sensitivity for CRC, this decreased from 97.0% at the 2 µg/g cutoff, to 90.9% at the 10 µg/g cutoff, and 70.8% at the 150 µg/g cutoff. Specificity increased from 64.9% to 83.5% and 94.6%, respectively.

The authors concluded that a higher hemoglobin cutoff could be set to match capacity in resource-limited settings, which would reduce the number of positive results, onwards referral for investigation and demand for colonoscopy but at the expense of detecting fewer cancers. The study was published on October 21. 2020 in the journal GUT.

Related Links:
Croydon University Hospital
Hitachi Chemical Diagnostics Systems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.